Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 89

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 89
---
Work in process18,694 26,725 Finished goods22,065 16,441 Total$49,423 $54,293 

18

Property and Equipment, Net March 31,2025December 31,2024(unaudited)Lab equipment and furniture$13,760 $13,370 Leasehold improvements14,023 14,023 Software883 883 Computer equipment1,112 1,112 29,778 29,388 Less accumulated depreciation and amortization(18,440)(17,843)Property and equipment, net$11,338 $11,545 Depreciation and amortization expense on property and equipment was approximately $0.6 million for the three months ended March 31, 2025 and $0.6 million for the three months ended March 31, 2024, respectively.

Accounts Payable and Accrued LiabilitiesMarch 31,2025December 31,2024(unaudited)Accounts payable$7,072 $4,587 Accrued compensation, benefits, & related accruals17,596 21,225 Accrued sales & marketing14,832 11,007 Accrued manufacturing expenses11,067 11,652 Accrued R&D expenses5,413 5,898 Operating lease liabilities, current portion (1)5,937 6,889 Accrued royalties (2)6,250 8,105 Other accrued expenses8,724 6,989 Total$76,891 $76,352 _______________________________(1)  Refer to Note 12, Leases.(2)  Refer to Note 15, Commitments and Contingencies.

Accrued Product Returns and RebatesMarch 31,2025December 31,2024(unaudited)Accrued product rebates$120,208 $115,330 Accrued product returns49,925 53,375 Total$170,133 $168,705 

15.    Commitments and Contingencies

Product LicensesThe Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third